

CURRICULUM VITAE

Dr. Nimer Alkhatib, PharmD, MS, PhD

Pharmacy/Assistant Professor of

Pharmacoeconomics, Policy, and Health Outcomes

Al-Zaytoonah University of Jordan, Amman, Jordan

Phone: 00962-6-4291511

Fax: 00962-6-4291432

E-mail: n.alkhatib@zuj.edu.jo



1. Personal Data

Date of Birth: 2 January 1987 (Manhattan, KS, USA)

Nationality: USA and Jordan

2. Education

- Ph.D. (Pharmaceutical economics, policy, and health outcomes) 2020, University of Arizona, Tucson, Arizona, USA
- Certificate (Business Entrepreneurship), 2019 Arizona State University (ASU), Phoenix, Arizona
- M.Sc. (Pharmaceutical economics, policy, and health outcomes) 2017, University of Arizona, Tucson, Arizona, USA
- B.Sc. (PharmD) 2011, Jordan University of Science and Technology, Irbid, Jordan

3. Ph.D. Dissertation

Innovative methods for outcome-based pricing treatments from the US payer perspective (the six-delta platform)-University of Arizona, Tucson, USA.

4. Employment

Academic Positions



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

- Assistant Professor of Pharmacoeconomics, Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
February 23, 2020 – now
- Associate Consultant, Matrix45 Evidence-Based Healthcare, Tucson, USA
April 20, 2020 – Now
- Adjunct Assistant Professor, Pharmacy Practice and Science, University of Arizona, Tucson, USA
February 20, 2020 – Now
- Designated Campus Colleague/ Associate, Center for Health Outcomes and PharmacoEconomic Research (HOPE Center), University of Arizona, USA
March 7, 2020 – Now
- Pre-doctoral fellow, Center for Health Outcomes and PharmacoEconomic Research (HOPE Center), University of Arizona, USA
August 15, 2015, December 30, 2019

Research Positions

2023-present	JOURNAL OF MEDICAL ECONOMIC. Early Career Panel
2022 – present	EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. Reviewer
2022 – present	SAUDI PHARMACEUTICAL JOURNAL. Reviewer
2022 – present	POSTGRADUATE MEDICINE. Reviewer
2022 – present	JOURNAL OF MEDICAL ECONOMIC. Reviewer
2021 – present	JORDAN JOURNAL OF ECONOMIC SCIENCES. Reviewer
2021 – present	THE EUROPEAN JOURNAL OF HEALTH ECONOMICS. Reviewer
2020 – present	CURRENT MEDICAL RESEARCH & OPINION. Reviewer
2020 – present	JOURNAL OF HUMAN HYPERTENSION. Reviewer
2020 – present	JORDAN JOURNAL OF PHARMACEUTICAL SCIENCES. Reviewer
2020 – present	JOURNAL OF DRUG ASSESSMENT. Reviewer
2020 – present	JAMA DERMATOLOGY. Reviewer
2020 – present	JOURNAL OF TAIBAH UNIVERSITY. Reviewer.
2017 – present	ARIZONA DEPARTMENT OF HEALTH SERVICES FUNDED ECONOMIC PROJECTIONS FOR SMOKING CESSATION PROGRAMS (Phoenix, AZ, USA). Research Group Leader.
2017 – present	JOURNAL OF CLINICAL THERAPEUTICS (Philadelphia, PA, USA). Editorial Board Consultant.



QFG11/0110 - 3.1E	Curriculum Vitae Form - Procedures of Appointment and Promotion Committee
-------------------	---

2016 – present	CENTER FOR HEALTH OUTCOMES AND PHARMACOECONOMIC RESEARCH (Tucson, AZ, USA). Hematology and Oncology Research Group Leader.
2010 – 2011	INTERNATIONAL PHARMACEUTICAL STUDENTS' FEDERATION (IPSF) (Amman, JORDAN). Regional Projects Officer for Eastern Mediterranean Region.
2009 – 2010	WORLD HEALTH ORGANIZATION (W.H.O.) (Amman, Jordan). Clinical Data coordinator for a project sponsored by Harvard University on chronic diseases.

5. Research Interests

- Value-based pricing, Oncology, Biosimilars, Cost-effectiveness, Modelling, Outcome Research.

6. Honors and Awards

- Academic excellence, 2016, University of Arizona, USA
- Academic excellence, 2017, University of Arizona, USA
- Academic excellence, 2018, University of Arizona, USA
- Academic excellence, 2019, University of Arizona, USA

7. Fellowships and Scholarships

- Full scholarship-PhD in Pharmacoeconomics, policy, and health outcome- Sponsored by the University of Arizona, USA 2017-2020
- Partial Scholarship- Certificate of Business Entrepreneurship sponsored by Arizona State University (ASU)
- Full scholarship-Summer School-Genomics and Science of Symptom Management by the University of Basel, Switzerland 2016-2016
- Full scholarship-MS in Pharmacoeconomics, policy, and health outcome- Sponsored by the University of Arizona, USA 2015-2017

9. Teaching Experience

• *Graduate Courses*

- Health Technology Assessment. College of Pharmacy, University of Arizona, Tucson, USA
- Applied Health Technology Assessment, College of Pharmacy, University of Arizona, Tucson, USA



- **Undergraduate Courses**

- Pharmacoeconomics, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
- Pharmaceutical marketing, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
- Pharmacy practice (applied), College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
- Communication skills in pharmacy practice, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan

10. Supervision of Graduate Research

- Mais Maghaireh: For Master's degree in pharmaceutical sciences 2020-2022
- Hala Halawah: For Master's degree in pharmaceutical sciences 2020-2022
- Mavis Obeng-Kusi: for PhD studies, health technology assessment project 2020-2020
- Evelyn Kim: For senior project-PharmD. University of Arizona 2016-2017
- Yazan Barqawi: For Master's degree in Pharmaceutical Economics. University of New Mexico 2017-2018
- Neda Alrawashdh: For Master's degree in Clinical Translational Sciences. University of Arizona 2018-2020
- Briana Choi: For senior project-PharmD. University of Arizona 2018-2019
- Elizabeth Pae: For senior project-PharmD. University of Arizona 2018-2019
- Kelly Yiu: For senior project-PharmD. University of Arizona 2018-2019

11. Grants

- Principal investigator. Economic Burden of Smoking in Jordan. Grant ID: 29/10/2022-2023. Amount JOD 6,500
- Principal investigator. Economic evaluation of f Olanzapine, neurokinin-1 receptor antagonist, and thalidomide in combination with palonosetron and dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Umm Al-Qura University, Makkah, Saudi Arabia. Budget: Confidential
- Analyst. Evaluation of smoking cessation clinics and behavior of clients. Department of Family Medicine/ College of Medicine/ University of Arizona. Under Prof. Ivo Abraham. Budget: Confidential
- Analysis group leader "Economic evaluation of smoking cessation vs. persistence for a panel of ~200,000 Arizonans who quit cigarette smoking between 1/1/2011 and 12/31/2015." Arizona Department of Health Services (2017-2018). Direct costs: \$213,450.



12. Professional and Scientific Meetings

Scientific Meetings Organized

- Jordan Pharmaceutical Association 16th conference. Amman, Jordan. 2023
- Jordan University of Science and Technology International Conference. Irbid, Jordan. 2023
- Jordan Food and Drug Administration Annual Conference. Amman, Jordan. 2023
- HTA capability building training. Ministry of Defense. Saudi Arabia, 2023
- ISPOR Saudi Annual Conference, June 2023
- Value Assessment Of Disease-Modifying Therapies For Multiple Sclerosis: Current And Future Initiatives, Amman, Jordan, 2022
- ASCOP, Algeria, 2022
- Evidence Based Medicine & Pharmacoeconomic Summit, Amman, Jordan, 2020
- ACCC 35th National Oncology Conference, Phoenix, USA, 2018
- American Society of Clinical Oncology, Chicago, USA, 2018
- American Society of Hematology, Atlanta, USA, 2017
- Western Pharmacoeconomic Conference, New Mexico, USA 2017

Participation in Scientific meetings

Abstracts presented and published

1. Almutairi A, Alkhatib N, Maghaireh M, Halloush S, Rashdan O, Manasrah A, Khassawaneh A, Mayaatah A, Saleh M, Abumansour H, Abraham A. Real-World Effectiveness Of Osimertinib In Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutation: Systematic Review and Meta-analysis. Value in Health 2023
2. Obeng-Kusi M, Arku D, Alrawashdh N, Choi B, **Alkhatib N**, McBride A, Abraham I. Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM) - A comparative cost-effectiveness analysis. Journal of Clinical Oncology 2021.
3. **Alkhatib N**, Choi B, Halawah H, Calamia M, Gulick DL, Manasrah A, Alkhdour A, McBride A, Abraham I. Economic evaluation of crizotinib, alectinib, ceritinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) as second line treatment. Journal of Clinical Oncology 2021.
4. Choi B, **Alkhatib N**, Halawah H, Calamia M, Gulick DL, Manasrah A, Alkhdour A, McBride A, Abraham I. Economic evaluation of crizotinib, alectinib, ceritinib and brigatinib in treatment naïve anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2021.
5. Bin Riaz I, Almutairi A, Lang DK, Asghar N, Riaz A, Yao Y, Sipra Q, Ryu AJ, **Alkhatib N**, Oh M, Abraham I, Murad MH, Kohli M. Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology 2020.
6. **Alkhatib N**, Choi B, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS). American Society of Clinical Oncology (ASCO) 2019 USA.
7. Choi B, **Alkhatib N**, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase

- positive (ALK+) non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) 2019 USA.
8. Alrawashdh N, **Alkhatib N**, McBride A, Persky D, Abraham I. Economic Evaluation for the US of Ibrutinib versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. American Society of Hematology (ASH) 2018 USA
 9. **Alsaid N**, McBride A, Abraham I. Economic Evaluation for the US of Ibrutinib versus Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Clinical Oncology (ASCO) 2018 USA
 10. Oh M, Almutairi A, **Alsaid N**, Babiker H, McBride A, Abraham I. Progression-Free (PFS) and Overall Survival (OS) in Treatment of BRAF Mutation-Positive Metastatic Melanoma: Bayesian Network Meta-Analysis. American Society of Clinical Oncology (ASCO) 2018 USA
 11. **Alsaid N**, McBride A, Oh M, Persky D, Anwer F, Andritsos L, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
 12. **Alsaid N**, McBride A, Kim H, Oh M, Andritsos L, Anwar F, Persky D, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Ibrutinib versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
 13. **Alsaid N**, Sweitzer N, Ramos N, Abraham I. Systematic Review for Causes of Hospitalization in Cost-Effectiveness Studies. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Europe
 14. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Economic Evaluation of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). World Congress of Pharmacy and Pharmaceutical Sciences (FIP) 2017 South Korea
 15. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Cost-Effectiveness of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). American Society of Clinical Oncology (ASCO) 2017 USA
 12. **Alsaid N**, McBride A, Abraham I. Cost-effectiveness of Daratumumab 10mg+Dacarbazine versus Dacarbazine Alone in Metastatic/Advanced Melanoma. Western Pharmacoeconomics Conference 2017 USA
 13. **Alsaid N**, Almutairi1 A, Fazel M, Lee J, Slack M. Information Required in Research Reports for Inclusion in Meta- analysis: Cohort Studies for Evaluating the Impact of Pharmacist Care on Diabetes Outcomes. American Society of Health-System Pharmacists (ASHP) midyear scientific sessions 2016 USA

13. Presentations and Lectures Invited

1. **Alkhatib N**. Economic value of Infliximab SC in Saudi, Biotech regional conference, Istanbul, Turkey, 2023
2. **Alkhatib N**. Budget impact of FYB203 in Saudi, MS Pharma Launching FYB203, Jeddah, Saudi Arabia, 2023
3. **Alkhatib N**. Value of Biosimilars in Jordan, MS Pharma Launching Uptera, Amman, Jordan, 2023
4. **Alkhatib N**. Value of Biosimilars in MENA region, JFDA conference, Amman, Jordan, 2023



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

5. **Alkhatib N.** Value of Biosimilars in MENA region, JFDA conference, Amman, Jordan, 2023
6. **Alkhatib N.** Value Assessment Of Disease-Modifying Therapies For Multiple Sclerosis: Current And Future Initiatives, Amman, Jordan, 2023
7. **Alkhatib N.** Pharmacoeconomic evaluation in Jordan settings, Algeria, Algeria, 2022.
8. **Alkhatib N.** Outcomes data for researchers in low- and mid-income countries, Applied Science University, Amman, Jordan, 2022
9. **Alkhatib N.** Six Delta Platform sessions for Otsuka Pharmaceuticals, New Jersey, USA, 2021 to 2022.

14. Invited Interviews

- **Alkhatib N.** Integrating Biosimilars Within a Community, Academic, or Health-System Setting. 2019: <https://www.accc-cancer.org/home/learn/immunotherapy/resource-detail/integrating-biosimilars-within-a-community-academic-or-health-system-setting>
- **Alkhatib N, McBride A, Earl M, Patel K.** Expert Panel Discusses the Financial and Economic Impact of Biosimilars Targeted Oncology 2018. <https://www.targetedonc.com/conference/accc-noc-2018/expert-panel-discusses-the-financial-and-economic-impact-of-biosimilars>
- **Alsaid N.** Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia. AJMC Managed Markets Network 2018. <https://www.ajmc.com/conferences/ash-2017/ibrutinib-more-effective-than-stemcell-transplant-in-patients-with-form-of-chronic-leukemia>

15. Organizational Services

- National Committee for Revising Drug Pricing Policy, JFDA. Jordan (2023-present)
- HTA rare diseases in Jordan, Ministry of Health. Jordan (2022-present)
- ISPOR Saudi Chapter. Saudi Arabia (2023-present)
- Research Group Leader for Arizona Health Department Funded Project, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2017-present).
- Hematology and Oncology Research Group Leader, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2016-present).
- Post-Doc Trainer, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2016- present).
- Member, Jordanian Pharmaceutical Association. Jordan (2011-present).
- Social Chair, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), University of Arizona Chapter (2016-2017).
- Regional Project Officer, International Pharmaceutical Students' Federation (IPSF), Eastern Mediterranean Region (2010-2011).

16. Publications

Peer Reviewed Articles

Published



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

1. **Alkhatib N**, Halloush S, Abraham I. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region. Expert Opinion on Biological Therapy, 2023
2. Halawah H, **Alkhatib N**, Almutairi A, Masadh L, Mohammad Salah M, Abu Sarah O, Abraham I. Economic Modeling for Jordan of the Cost-Efficiency and Associated Expanded Treatment Access of Conversion to Rituximab Biosimilar from Reference Rituximab. Journal of Medical Economics, 2023
3. Alamer A, Almutairi, A R, Halloush S, Al-Jedai A, Alrashed A, AlFaifi M, Mohzari Y, Almutairi M, AlHassar F, Howaidi J, Almutairi W, Abraham I, **Alkhatib N**. Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*, 2023
4. Halloush S, **Alkhatib N**, Almutairi AR, Calamia M, Halawah H, Obeng-Kusi M, Hoyle M, Rashdan O, Koeller J, Abraham I. Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective. *Annals of Pharmacotherapy* 2023
5. Alrawashdh N, McBride A, Oh M, **Alkhatib N**, Lee C, Martin J, MacDonald K, Abraham I. Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type. *Journal of the Advanced practitioner in Oncology* 2022
6. **Alkhatib N**, Almutairid A, Alkhezie O, Alfayeze O, Al Yami M, Almohammed O. Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. *Saudi pharmaceutical Journal* 2022
7. Halloush S, Alhifany AA, **Alkhatib N**, Albawab A, AL-Qawasmeh B, Al Shawakri E, Koeller J. Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting. *Current Medical Research and Opinion* 2022
8. Al-Qerem W, Al Bawab A, Abusara O, **Alkhatib N**, Horne R. Validation of the Arabic version of Medication Adherence Report Scale questionnaire and Beliefs about Medication Questionnaire- -Specific questionnaires: A factor analysis study. *PLOS* 2022
9. Al Bawab A, Al-Qarem W, Abusara O, **Alkhatib N**, Mansour M, Horne R. What are the factors associated with nonadherence to medications in patients with chronic diseases. *Healthcare* 2021.
10. **Alkhatib N**, Sun D, Denhaerynck K, Harmaneh D, Camp YV, Villa L, Brié H, Vancayzeele S, MacDonald K, Abraham I. Hierarchical Modeling of Blood Pressure Determinants and Outcomes Following Valsartan Treatment in Hypertensive Patients with Known Comorbidities: Pooled Analysis of Six Prospective Real-World Studies Including 11,999 Patients. *Current Medical Research & Opinion* 2021.
11. Harmaneh D, **Alkhatib N**, Denhaerynck K, Vancayzeele S, Brié H, Aerts A, MacDonald K, Abraham I. Gender-Stratified Hierarchical Modeling of Patient and Physician Determinants of Antihypertensive Treatment Outcomes: Pooled Analysis of 7 Prospective Real-World Studies with 17,044 Patients. *Current Medical Research & Opinion* 2021.

Articles 12 to 19 as a special issue in the Journal of Medical Economics

12. **Alkhatib N**, Abraham I. The Six Delta Platform for Outcome-Based Contracting for Pharmaceuticals *Journal of Medical Economics* 2020.
13. **Alkhatib N**, Ramos K, Erstad B, Slack M, McBride A, Bhattacharjee S, Abraham I. Pricing Methods in Outcome-Based Contracting: $\delta 1$: Cost Effectiveness Analysis and Cost-Utility Analysis-Based Pricing. *Journal of Medical Economics* 2020.
14. **Alkhatib N**, Ramos K, Erstad B, Slack M, McBride A, Bhattacharjee S, Abraham I. Pricing Methods in Outcome-Based Contracting: $\delta 2$: Willingness-To-Pay-Based Pricing. *Journal of Medical Economics* 2020.
15. **Alkhatib N**, Erstad B, Ramos K, McBride A, Bhattacharjee S, Slack M, Abraham I. Pricing Methods: $\delta 3$: Reference-Based Pricing. *Journal of Medical Economics* 2020.



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

16. **Alkhatib N**, Bhattacharjee S, McBride A, Ramos K, Slack M, Erstad B, Abraham I. Pricing Methods in Outcome-Based Contracting: δ_4 : Safety-Based Pricing. *Journal of Medical Economics* 2020.
17. **Alkhatib N**, McBride A, Bhattacharjee S, Ramos K, Erstad B, Slack M, Billheimer D, Abraham I. Pricing Methods in Outcome-Based Contracting: δ_5 : Risk of Efficacy Failure-Based Pricing. *Journal of Medical Economics* 2020.
18. **Alkhatib N**, Slack M, Bhattacharjee S, Erstad B, Ramos K, McBride A, Abraham I. Pricing Methods in Outcome-Based Contracting: δ_6 : Adherence-Based Pricing. *Journal of Medical Economics* 2020.
19. **Alkhatib N**, McBride A, Slack M, Bhattacharjee S, Erstad B, Ramos K, Abraham I. Pricing Methods in Outcome-Based Contracting: Integration Analysis of the Six Dimensions (6 δ 's). *Journal of Medical Economics* 2020.
20. **Alkhatib N**, Sweitzer N, Erstad B, Slack M, Gharaibeh M, Karnes J, Larriva M, Klimecki W, Ramos N, Abraham I. Ex Ante Economic Evaluation of Bucindolol vs. Carvedilol with and without Arg389 Beta1-Adrenergic Receptor Polymorphism Testing in Stage III/IV Heart Failure. *American Journal of Cardiovascular Drugs* 2020.
21. Hacene M, Saker M, Youcef A, Koudri S, Cheriet S, Mercouk H, Lounici A, **Alkhatib N**. Insulin injection technique in Western region of Algeria, Tlemcen. *Pan African Medical Journal* 2020
22. Oh M, Patanwala A, **Alkhatib N**, Almutairi A, Abraham I, Erstad B. Cost Benefit Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: US Payer Perspective. *Critical Care Medicine* 2020.
23. Andritsos L, McBride A, Huff K, Huang Y, Fan T, **Alkhatib N**, Abraham I, Drea E. Clinical and Cost Outcomes of Pre-Emptive Plerixafor Administration in Patients with Multiple Myeloma Undergoing Stem Cell Mobilization. *Leukemia Research* 2019.
24. Alfayez O, AlYami M, Alshibani M, Fallataha S, AlKhushaym N, Alsheikh R, **Alkhatib N**. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. *Primary Care Diabetes* 2019.
25. Almutairi A, Alkhatib N, Abraham I. The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs—Reply. *JAMA Dermatology* 2018.
26. Almutairi A, **Alkhatib N**, Oh M, Lewandrowski C, Babiker H, Cranmer L, McBride A, Abraham I. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients with Advanced Unresectable Melanoma. *JAMA Dermatology* 2018.
27. **Alkhatib N**, Ramos N, Sweitzer N, Slack M, Erstad B, Gharaibeh M, Klimecki W, Larriva M, Karnes J, Abraham I. Ex Ante Economic Evaluation of Genetic Testing for the Arg-389 Beta1-Adrenergic Receptor Polymorphism to Support Bucindolol Treatment Decisions in Stage III/IV Heart Failure. *Expert Review of Precision Medicine and Drug Development* 2018.
28. Kelley E, Snyder E, **Alkhatib N**, Snyder S, Sprissler R, Olson T, Akre M, Abraham I. Economic Evaluation of a Pharmacogenomic Multi-Gene Panel Test to Optimize Anti-Hypertension Therapy: Simulation Study. *Journal of Medical Economics* 2018.
29. Gharaibeh M, McBride A, Alberts D, Slack M, Erstad B, **Alsaid N**, Bootman J, Abraham I. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. *Pharmacoeconomics* 2018.
30. Gharaibeh M, McBride A, Alberts D, Slack M, Erstad B, **Alsaid N**, Bootman J, Abraham I. Economic Evaluation for UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. *Pharmacoeconomics* 2018.
31. Zhou L, Almutairi L, **Alsaid N**, Warholak T, Cooley J. Establishing the Validity and Reliability Evidence of Preceptor Assessment of Student Tool Designed to Assess Rotation Performance of Doctor of Pharmacy Students: A Rasch Analysis. *American Journal of Pharmaceutical Education (AJPE)* 2016.



Abstracts Accepted

32. Almutairi A, **Alkhatib N**, Maghaireh M, Halloush S, Rashdan O, Manasrah A, Khassawaneh A, Mayaatah A, Saleh M, Abumansour H, Abraham A. Real-World Effectiveness Of Osimertinib In Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutation: Systematic Review and Meta-analysis. Value in Health 2023
33. Obeng-Kusi M, Arku D, Alrawashdh N, Choi B, **Alkhatib N**, McBride A, Abraham I. Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM) - A comparative cost-effectiveness analysis. Journal of Clinical Oncology 2021.
34. **Alkhatib N**, Choi B, Halawah H, Calamia M, Gulick DL, Manasrah A, Alkhdour A, McBride A, Abraham I. Economic evaluation of crizotinib, alectinib, ceritinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) as second line treatment. Journal of Clinical Oncology 2021.
35. Choi B, **Alkhatib N**, Halawah H, Calamia M, Gulick DL, Manasrah A, Alkhdour A, McBride A, Abraham I. Economic evaluation of crizotinib, alectinib, ceritinib and brigatinib in treatment naïve anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2021.
36. Bin Riaz I, Almutairi A, Lang DK, Asghar N, Riaz A, Yao Y, Sipra Q, Ryu AJ, **Alkhatib N**, Oh M, Abraham I, Murad MH, Kohli M. Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology 2020.
37. **Alkhatib N**, Choi B, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS). American Society of Clinical Oncology (ASCO) 2019 USA.
38. Choi B, **Alkhatib N**, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) 2019 USA.
39. Alrawashdh N, **Alkhatib N**, McBride A, Persky D, Abraham I. Economic Evaluation for the US of Ibrutinib versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. American Society of Hematology (ASH) 2018 USA
40. **Alsaid N**, McBride A, Abraham I. Economic Evaluation for the US of Ibrutinib versus Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Clinical Oncology (ASCO) 2018 USA



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

41. Oh M, Almutairi A, **Alsaid N**, Babiker H, McBride A, Abraham I. Progression-Free (PFS) and Overall Survival (OS) in Treatment of BRAF Mutation-Positive Metastatic Melanoma: Bayesian Network Meta-Analysis. American Society of Clinical Oncology (ASCO)2018 USA
42. **Alsaid N**, McBride A, Oh M, Persky D, Anwer F, Andritsos L, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
43. **Alsaid N**, McBride A, Kim H, Oh M, Andritsos L, Anwar F, Persky D, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Ibrutinib versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
44. **Alsaid N**, Sweitzer N, Ramos N, Abraham I. Systematic Review for Causes of Hospitalization in Cost-Effectiveness Studies. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Europe
45. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Economic Evaluation of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). World Congress of Pharmacy and Pharmaceutical Sciences (FIP) 2017 South Korea
46. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Cost-Effectiveness of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). American Society of Clinical Oncology (ASCO) 2017 USA
47. **Alsaid N**, McBride A, Abraham I. Cost-effectiveness of Daratumumab 10mg+Dacarbazine versus Dacarbazine Alone in Metastatic/Advanced Melanoma. Western Pharmacoeconomics Conference 2017 USA
48. **Alsaid N**, Almutairi1 A, Fazel M, Lee J, Slack M. Information Required in Research Reports for Inclusion in Meta- analysis: Cohort Studies for Evaluating the Impact of Pharmacist Care on Diabetes Outcomes. American Society of Health-System Pharmacists (ASHP) midyear scientific sessions 2016 USA

Disclosure and Acknowledgment:

I certify that, to the best of my knowledge, the information contained in this Curriculum Vitae is accurate.

© Nimer Alkhatib, 2023. All rights reserved.